Gaudium IVF and Women Health Limited has submitted its Monitoring Agency Report for the quarter ended September 30, 2026. The report, issued by Infomerics Valuation and Rating Limited, details the utilization of proceeds from the company’s Initial Public Offer (IPO). Key objects monitored include funding capital expenditure for new IVF centers, repayment of borrowings, and general corporate purposes.
Monitoring Agency Report Filed for Q3 2026
Gaudium IVF and Women Health Limited has officially submitted its Monitoring Agency Report for the financial quarter that concluded on September 30, 2026. This report, prepared by Infomerics Valuation and Rating Limited, serves to track and verify the utilization of funds raised during the company’s Initial Public Offering (IPO).
Key Areas of Monitoring
The report focuses on several key objectives for which the IPO proceeds were allocated. These include:
- Funding capital expenditure towards the establishment of new IVF Centres, with an original cost of ₹50.00 crore.
- Repayment or pre-payment of certain outstanding borrowings, initially earmarked at ₹20.00 crore.
- General Corporate Purposes, with a revised allocation of ₹14.20 crore.
- Issue Expenses, amounting to ₹7.72 crore.
Utilization Progress
For the quarter ended September 30, 2026, the company reported utilizing ₹16.62 crore from the IPO proceeds. Notably, the establishment of new IVF centres saw an expenditure of ₹13.48 crore during this period, while ₹2.83 crore was utilized under General Corporate Purposes. The repayment of borrowings has been completed as per the offer document.
Deviations and Reallocations
The report indicates a deferment in the utilization of a portion of IPO proceeds earmarked for capital expenditure towards new IVF centres. The Board has noted this deferment and revised the timeline for incurring this expenditure. Furthermore, an unutilized balance of ₹1.93 crore from the borrowing repayment object was reallocated towards General Corporate Purposes, a move approved by the Board of Directors.
The Monitoring Agency has verified the utilization of funds based on information provided by the company, including bank statements, statutory auditor certificates, and management undertakings. The report confirms that the utilization of funds aligns with the disclosures made in the Offer Document, with no material deviations observed regarding shareholder approval for expenditures.
The report also details the deployment of unutilized IPO proceeds held in various instruments, including fixed deposits and current accounts, as of September 30, 2026. The total unutilized IPO proceeds amount to ₹39.35 crore.
Source: BSE
